

Catalog #10-4228 Mirabegron

CAS 223673-61-8

 $2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl] acetamide; (R)-2-(2-Aminothiazol-4-yl)-4'-\{2-[(2-hydroxy-2-phenylethyl)amino]ethyl\} acetanilide; YM178$

Lot # FBS4007

Mirabegron is a potent (EC₅₀ = 22.4 nM CHO cells expressing human \Re_3 -ARs) beta-3 adrenergic receptor (\Re_3 -AR) agonist with high selectivity over the beta-1 and beta-2 receptors. Clinically useful for the treatment of overactive bladder syndrome. Chronic treatment of human subjects with mirabegron increased brown adipose tissue (BAT) metabolic activity, increased HDL and bile acid levels, and produced substantial improvements in glucose and insulin metabolism. Mirabegron inhibited tumor growth in various tumor models including pancreatic ductal adenocarcinoma and hepatocellular carcinoma *via* altering global metabolism in an uncoupling protein 1 (UCP1; a key protein for non-shivering thermogenesis) dependent manner.

- 1) Takasu et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function; J. Pharmacol. Exp. Ther. **321** 642
- 2) O'Mara et al. (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity; J. Clin. Invest. **130** 2209
- 3) Sun et al. (2023) Mirabegron displays anticancer effects by globally browning adipose tissues; Nat. Commun. 14 7610

PHYSICAL DATA

Molecular Weight: 396.51

Molecular Formula: $C_{21}H_{24}N_4O_2S$ Purity: >98% HPLC

NMR: (Conforms)

Solubility: DMSO (at least 40 mg/ml)

Physical Description: Beige solid

Storage and Stability: Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.